Source comparison
MK-677 Vial Formats: Full Comparison
| Vial Format | Reconstitution Volume | Final Concentration | Target Dose | Withdrawal Volume/Dose | Total Doses | Best Use Case ||—|—|—|—|—|—|| 5mg vial | 1mL | 5mg/mL | 0.25mg | 50μL | 20 | Short pilot studies, dose-response testing || 10mg vial | 2mL | 5mg/
This comparison does not assign a generated winner or score.
- | Vial Format | Reconstitution Volume | Final Concentration | Target Dose | Withdrawal Volume/Dose | Total Doses | Best Use Case ||—|—|—|—|—|—|| 5mg vial | 1mL | 5mg/mL | 0.25mg | 50μL | 20 | Short pilot studies, dose-response testing || 10mg vial | 2mL | 5mg/mL | 0.5mg | 100μL | 20 | Standard 4-week research cycles || 15mg vial | 1.5mL | 10mg/mL | 0.3mg | 30μL | 50 | Extended protocols with daily administration || 20mg vial | 2mL | 10mg/mL | 0.5mg | 50μL | 40 | Multi-month studies requiring consistent dosing || 25mg vial | 2.5mL | 10mg/mL | 0.25mg | 25μL | 100 | Large-scale or long-duration research programs |
- The 10mg vial reconstituted with 2mL bacteriostatic water represents the most common research format. It balances dose count (20 doses at 0.5mg each), measurement accuracy (100μL per dose), and refrigerated shelf life (28 days post-reconstitution). Larger vials (20mg, 25mg) provide economy of scale for extended studies but require completion within the 28-day bacteriostatic water stability window—unused peptide after that point risks microbial contamination even under refrigeration.